VAXX is a speculative penny biotechnology NASDAQ stock with high volatility. On the 2H chart, it is currently trending up from a swing low
on April 25 with earnings to be reported Monday 5/8. May's relative volume compared with that of April is about 2-3X higher. To confirm
the bullish bias, VAXX is currently trading above its intermediate-term POC line on the volume profile. This confirms buyers as being in
control. Although this is speculative as are all biotechnology penny stocks, impending earnings as a catalyst has been considered.
Continued development in the vaccine subsector at large may suggest VAXX may have a favorable report to fuel further price action.
on April 25 with earnings to be reported Monday 5/8. May's relative volume compared with that of April is about 2-3X higher. To confirm
the bullish bias, VAXX is currently trading above its intermediate-term POC line on the volume profile. This confirms buyers as being in
control. Although this is speculative as are all biotechnology penny stocks, impending earnings as a catalyst has been considered.
Continued development in the vaccine subsector at large may suggest VAXX may have a favorable report to fuel further price action.